500
501
502
503

Address: Otfried-Müller-Straße 10
72076 Tübingen


Founding Director

frontend.sr-only_#{element.icon}: +49 7071 29-82168
Prof. Dr. Julia Skokowa


frontend.sr-only_#{element.icon}: julia.skokowa@med.uni-tuebingen.de


Scientific coordinator

frontend.sr-only_#{element.icon}: +49 7071 29-86013
Dr. Olga Klimenkova


frontend.sr-only_#{element.icon}: Olga.Klimenkova@med.uni-tuebingen.de


AG Reisinger

Portraitfoto

Prof. Dr. rer. nat. Ellen Reisinger

Department of Otolaryngology, Head and Neck Surgery

Person profile: More about the person

Gene Therapy for Hearing Impairment

Prof. Reisinger’s research group focuses on the physiology and pathophysiology of the inner ear. Specifically, the group is interested in deciphering the mechanisms behind genetic hearing loss. As such, the group studied the protein otoferlin, which is required for synaptic transmission from the auditory sensory cell. For the form of deafness caused by mutations in the underlying gene OTOF, they designed a gene therapy using two adeno-associated viruses, a so-called “Dual-AAV” approach. The ultimate goal is to develop gene therapeutic approaches for more forms of inherited hearing loss.

Wissenschaftliche Abbildung
From: Al-Moyed et al., 2019, EMBO Mol Med

List of GRT projects

  • Optimization of Dual-AAV gene therapy for inherited deafness DFNB9 (due to mutations in the OTOF gene)
  • More forms of inherited hearing loss coming soon


GRT expertise

  • AAV design, Dual-AAV design, AAV production
  • Genetics of Hearing Impairment


Main GRT methods applied in the lab

AAV design, production, purification, delivery


Ongoing and requested funding

  • From German Research Foundation (DFG):
  • Heisenberg-Program for Gene Therapy for Hearing impairment
  • Research Grant for Gene Therapy for Hearing impairment 
  • Research Training Group (RTG2816) for non-canonical G protein signaling

Publications

  • Dual-AAV delivery of large gene sequences to the inner ear.

    Reisinger E. Hear Res. 2020 Sep 1;394:107857. doi: 10.1016/j.heares.2019.107857. Epub 2019 Nov 28. PMID: 31810595 Free article. Review.

  • A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice.
    Al-Moyed H, Cepeda AP, Jung S, Moser T, Kügler S, Reisinger E. EMBO Mol Med. 2019 Jan;11(1):e9396. doi: 10.15252/emmm.201809396. PMID: 30509897


More publiactions


Relevante Links:

Relevant Links

Based on the research of the Reisinger group, a US start-up further developed the dual-AAV gene therapy for OTOF and will start clinical trials for gene therapy for DFNB9 soon. See: